We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.47B
AUM Growth
-$458M
Cap. Flow
+$15.5M
Cap. Flow %
0.35%
Top 10 Hldgs %
43.81%
Holding
163
New
19
Increased
16
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$65.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$64M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$58.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.3M
5
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$43.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$65.4M
2
XLRN
Acceleron Pharma
XLRN
+$52.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.8M
4
SEER icon
Seer Inc
SEER
+$28.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82%
2 Consumer Discretionary 6.51%
3 Financials 0.67%
4 Consumer Staples 0.51%
5 Materials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLT
101
DELISTED
Applied Therapeutics
APLT
$6.64M 0.15%
400,000
– –
ADVM
102
DELISTED
Adverum Biotechnologies
ADVM
$6.51M 0.15%
300,000
– –
TCRR
103
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$6.38M 0.14%
750,000
– –
STOK icon
104
Stoke Therapeutics
STOK
$1.81B
$6.36M 0.14%
250,000
– –
ALPN
105
DELISTED
Alpine Immune Sciences Inc
ALPN
$6.33M 0.14%
593,030
– –
IMUX icon
106
Immunic
IMUX
$177M
$6.2M 0.14%
70,000
– –
CFRX
107
DELISTED
ContraFect Corporation
CFRX
$6.08M 0.14%
18,750
– –
YI
108
111 Inc
YI
$33.4M
$5.96M 0.13%
96,635
– –
FUSN
109
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$5.94M 0.13%
750,000
– –
DSGN icon
110
Design Therapeutics
DSGN
$748M
$5.88M 0.13%
400,000
– –
GDS icon
111
GDS Holdings
GDS
$5.92B
$5.66M 0.13%
+100,000
New +$6.16M
OLPX
112
DELISTED
Olaplex Holdings
OLPX
$5.51M 0.12%
+225,000
New +$5.51M
CRDF icon
113
Cardiff Oncology
CRDF
$60.9M
$5M 0.11%
750,000
– –
SNTI icon
114
Senti Biosciences Holdings
SNTI
$11.1M
$4.97M 0.11%
50,000
– –
WVE icon
115
Wave Life Sciences
WVE
$1.12B
$4.9M 0.11%
+1,000,000
New +$6.06M
ARAV
116
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.88M 0.11%
1,311,291
– –
RXRX icon
117
Recursion Pharmaceuticals
RXRX
$1.59B
$4.6M 0.1%
200,000
– –
ORTX
118
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.15M 0.09%
180,386
– –
IMMP
119
Immutep
IMMP
$56.8M
$3.87M 0.09%
1,000,000
– –
PFTA
120
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.8M 0.09%
+380,000
New +$3.67M
MREO
121
Mereo BioPharma
MREO
$50.7M
$3.63M 0.08%
1,500,000
– –
HOOK
122
DELISTED
HOOKIPA Pharma
HOOK
$3.53M 0.08%
59,962
– –
RNAM
123
DELISTED
Avidity Biosciences
RNAM
$3.51M 0.08%
142,500
– –
DCPH
124
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.4M 0.08%
100,000
-100,000
-50% -$3.19M
CDAK
125
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$3.27M 0.07%
200,000
– –
3 4
5
6 7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2021 Portfolio in Review

As of Q3 2021, Artal Group held 163 positions worth $4.47B, down 9.3% from $4.93B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q3 2021 filing shows 19 new, 16 increased, 16 reduced and 17 closed positions. Its largest new stake was Erasca: 3,172,221 shares worth $67.3M. The largest sale was BeOne Medicines Ltd, an estimated $65.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q3 2021 buy was Erasca: 3,172,221 shares worth $67.3M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $56.3M increase.
  • Artal Group's biggest Q3 2021 reduction was BeOne Medicines Ltd, cutting an estimated $65.4M.
  • Artal Group fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021, selling an estimated $38.8M.
  • Artal Group's ten largest holdings make up 44% of its $4.47B portfolio in Q3 2021.
  • Artal Group opened 19 new positions and closed 17 in Q3 2021.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $4.47B.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.